Moreover, one of TRPA1 inhibitor, GRC-17536 has been used in phase II clinical trials in the treatment of respiratory disorders and diabetic peripheral neuropathy (NCT01726413) [24, 25]. The gene discussed is TRPA1; the disease is respiratory system disorder.